Canada finally opens up data on new drugs and devices: Other regulators should take note of Health Canada’s substantive reforms
Authors
Advisor
Date
2019-04-17
Embargo until
Language
Book title
Publisher
BMJ Publishing Group
Peer Reviewed
Type
Article
Research Area
Jurisdiction
Collections
Other Titles
Abstract
Data Availibility
Data / Code Location
Table of Contents
Description
Authors discuss Health Canada’s revised regulations regarding releasing detailed clinical information about new drugs, biological treatments, and medical devices. They contrast the policies of the Canadian regulator and its European counterpart, the European Medicines Agency (EMA), with that of the US Food and Drug Administration (FDA) which has yet to demonstrate a similar commitment to transparency.
Citations
Altmetric: